Show simple item record

dc.contributor.authorYeh, Jennifer Een_US
dc.contributor.authorToniolo, Patricia Aen_US
dc.contributor.authorFrank, David Aen_US
dc.date.accessioned2014-03-11T13:24:55Z
dc.date.issued2013en_US
dc.identifier.citationYeh, Jennifer E, Patricia A Toniolo, and David A Frank. 2013. “JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.” JAK-STAT 2 (4): e24635. doi:10.4161/jkst.24635. http://dx.doi.org/10.4161/jkst.24635.en
dc.identifier.issn2162-3988en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879460
dc.description.abstractA recent article published by Britschgi et al. in Cancer Cell, “JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer,” describes a positive feedback loop of JAK2/STAT5 activation that drives resistance to PI3K/mTOR inhibition in breast cancer. The authors found that genetic or pharmacological inhibition of JAK2 circumvents resistance to PI3K/mTOR inhibition and go on to show the efficacy of combined PI3K/mTOR and JAK2 inhibition on reducing cancer cell number, tumor growth, and metastasis as well as increasing in vivo survival. These results provide strong support for combination therapy with JAK2/STAT5 and PI3K/mTOR inhibitors in breast cancer. Here we discuss how the article by Britschgi et al. proposes a novel mechanism to explain how breast cancer cells overcome inhibition of a key signaling pathway driving cell proliferation. We also discuss the interplay between activation of the transcription factors STAT5 and STAT3 in breast cancer.en
dc.language.isoen_USen
dc.publisherLandes Bioscienceen
dc.relation.isversionofdoi:10.4161/jkst.24635en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891630/pdf/en
dash.licenseLAAen_US
dc.subjectbreast canceren
dc.subjectkinasesen
dc.subjectsignal transductionen
dc.subjecttargeted therapyen
dc.subjecttranscription factorsen
dc.titleJAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibitionen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJAK-STATen
dash.depositing.authorYeh, Jennifer Een_US
dc.date.available2014-03-11T13:24:55Z
dc.identifier.doi10.4161/jkst.24635*
dash.contributor.affiliatedYeh, Jennifer
dash.contributor.affiliatedFrank, David


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record